Art Pappas will speak at the Drug Repositioning Summit on October 6 in Boston, MA
Methylgene announces the initiation of a Phase 2 trial of MGCD0103
MethylGene Inc. (TSX: MYG) announced today the initiation of a Phase II clinical trial (Trial 013) evaluating MGCD0103, an isoform-selective histone deacetylase (HDAC) inhibitor product candidate, in combination with Vidaza(R) (azacitidine for injection), a DNA demethylating agent, in patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML).
Jeff Collins was elected to a 3-year term on the Board of Directors of NCBIO at its annual meeting, in Winston-Salem, NC
NCBIO elected four new members to the organization’s Board of Directors and re-elected six other individuals at the annual meeting in Winston-Salem, May 19th. Jeff Collins, Executive in Residence, Pappas Ventures; Norris Tolson, President and CEO of the NC Biotechnology Center; Susan Thomason, Executive Director Global Business Development, NovaQuest; and Jan Turek, President and CEO of Biolex Therapeutics will serve until 2011.
